News|Articles|July 22, 2025

New precision fermentation program for bovine alpha-lactalbumin announced by 21st.BIO

Author(s)Erin McEvoy

Using a microbial strain from Novonesis, the program aims to provide an animal-free and scalable production of the milk protein using precision fermentation.

In a July 10, 2025, press release, fermentation technology company 21st.BIO announced the launch of a precision fermentation program for bovine alpha-lactalbumin (α-lac). The whey protein, found in both cow and human milk, contains significant amounts of essential amino acids and has been associated with support for cognitive and immune developments, the press release explains. Increased interest in the protein for use in functional foods, dietary supplements, and ready-to-drink beverages has also been seen, it adds.

“Alpha-lactalbumin is incredibly valuable, but current supply from cow’s milk is limited,” stated Thomas Schmidt, CEO of 21st.BIO, in the press release. “It is challenging and costly to extract at scale, which is why current supply is mostly reserved for the very high-end infant formula market. Through precision fermentation, we make production more efficient, sustainable, and – most importantly – available to many, not just the few. On top of this, we are able to produce α-lac of high purity, an important parameter for infant nutrition.”

The program launch comes after the company licensed the high-yield microbial strain from biosolutions company Novonesis. 21st.BIO intends to optimize the strain for industrial fermentation with the aim of being cost competitive. As the press release noted, one kilogram of α-lac is obtained from approximately one thousand liters of milk.

“We are proud to see our world-class strain being brought to market to solve current challenges in food and nutrition by 21st.BIO,” stated Thomas Batchelor, senior vice president of Advanced Health and Protein Solutions at Novonesis. “We continually strive to be at the forefront of innovation and this strain is one result of our pioneering work in R&D, strain development and production. We see α-lac as a great fit to 21st.BIO’s strategy and portfolio, making it the right path forward while we in Novonesis continue to focus on other protein innovation and we’re excited about the future of protein made with precision fermentation.”

The fermentation program aims to address the increasing global demand for milk proteins and challenges from decreasing production.

"We're heading for a protein supply gap,” added Schmidt. “The industry itself is telling us: We won't be able to meet future demand using traditional methods alone. Precision fermentation is a complementary solution – one that can reduce pressure on natural resources, lower environmental impact, and create a more distributed and resilient supply chain."

Newsletter

From ingredient science to consumer trends, get the intel you need to stay competitive in the nutrition space—subscribe now to Nutritional Outlook.